Cardiovascular Drug-Eluting Stents Market - Strategic Insights and Forecasts (2026-2031)

The Cardiovascular Drug-Eluting Stents Market is projected to grow at a CAGR of 8.2% during the forecast period, increasing from USD 12.46 billion in 2026 to USD 18.44 billion by 2031, driven by rising coronary artery disease prevalence and adoption of minimally invasive procedures.

In the Cardiovascular Drug-Eluting Stents Market, drug-eluting stents are coronary implants that release antiproliferative drugs to prevent restenosis while restoring blood flow in narrowed coronary arteries.

The Cardiovascular Drug-Eluting Stents Market is driven by increasing coronary artery disease burden, growing preference for minimally invasive interventions, technological advancements in stent design, and expansion of interventional cardiology infrastructure.

The Cardiovascular Drug-Eluting Stents Market is led by North America due to advanced cardiac care infrastructure, high procedural volumes, and strong reimbursement systems.

The Cardiovascular Drug-Eluting Stents Market is restrained by high device and procedural costs, risks of stent thrombosis and restenosis, strict regulatory requirements, and competition from alternative treatments.